



## BioAegis Therapeutics Hires Dr. Mark J. DiNubile as Chief Medical Officer to Spearhead Forthcoming Phase 2 Clinical Trials in Community-Acquired Pneumonia

BOSTON, MA and MORRISTOWN, NJ (**BIOAEGIS THERAPEUTICS**) October 13, 2017 BioAegis Therapeutics Inc., a privately held biotechnology company exploiting the role of plasma gelsolin (pGSN) in augmenting innate immunity announced that Mark J. DiNubile has joined the organization as Chief Medical Officer.

Dr. DiNubile brings to BioAegis the rare combination of clinical and research expertise along with broad pharmaceutical industry experience, coupled with his long-standing dedication to elucidating the clinical utility of plasma gelsolin. Mark is a board-certified physician in Internal Medicine and the subspecialty of Infectious Diseases and Fellow of the Infectious Disease Society of America (FIDSA). He joins BioAegis after 16 years at Merck & Co., Inc. where he was primarily focused on the therapeutic areas of Infectious Diseases and Vaccines. He has extensively published on a diverse spectrum of medical and scientific topics.

Dr. DiNubile graduated from the University of Pennsylvania *summa cum laude* and Yale School of Medicine, followed by internship and residency at the Hospital of the University of Pennsylvania. As a fellow at Harvard Medical School, he completed his clinical infectious diseases requirements at Brigham & Women's Hospital followed by research focusing on neutrophil motility and phagocytosis at the Massachusetts General Hospital. During this period, he conducted early work on plasma gelsolin in the laboratory of BioAegis's founding scientist, Dr. Thomas Stossel. For more than a decade, prior to joining industry at Merck, Mark cared for patients in the ambulatory and hospital setting; taught medical students, house officers and fellows; chaired the hospital Pharmacy and Therapeutics Committee; initiated an antibiotic-stewardship program; and pursued clinical investigation and basic research, largely related to host defense and immunosuppression.

Susan Levinson PhD, Chief Executive Officer of BioAegis Therapeutics commented, "We are delighted to have Mark join our team as we move forward with further clinical studies. He has a keen understanding of plasma gelsolin and given his extensive experience as an infectious disease physician, he intimately understands the pressing need for new therapies to combat the looming crisis of antibiotic resistance and its potential global impact."

According to Dr. DiNubile, "Given the recent scientific breakthroughs leading to an expanded understanding of plasma gelsolin's physiological role, restoring low levels of this endogenous protein could create a new treatment paradigm for infectious and non-infectious inflammatory diseases that would greatly benefit patients while reducing healthcare costs."



### **Plasma Gelsolin**

Plasma gelsolin (pGSN), a key component of the innate immune system, becomes depleted in a wide range of acute and chronic conditions involving injury and inflammation. Critically low levels associate with significant morbidity and mortality in animals and humans. In many independent laboratories, plasma gelsolin administration produces striking recoveries from lethal challenges including infection -- in the absence of antibiotic therapy -- strongly supporting the potential for utility in antibiotic resistance and chronic inflammatory conditions.

### **About BioAegis Therapeutics**

BioAegis Therapeutics Inc. is a private company whose mission is to harness the body's innate immune system to address adverse outcomes in diseases driven by inflammation and infection.

*This press release contains express or implied forward-looking statements, which are based on current expectations of management. These statements relate to, among other things, our expectations regarding management's plans, objectives, and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. BioAegis assumes no obligation to update any forward-looking statements appearing in this press release in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.*

### **For further information:**

Steven Cordovano, 203-952-6373

Email: [scordovano@bioaegistx.com](mailto:scordovano@bioaegistx.com)

[www.bioaegistx.com](http://www.bioaegistx.com)